Alumis Inc. (ALMS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Martin Babler Ph.D. | President, CEO & Chairman | 912.64k | -- | 1965 |
| Dr. David M. Goldstein Ph.D. | Chief Scientific Officer | 651.37k | -- | 1967 |
| Mr. Roy C. Hardiman J.D. | Chief Business & Strategy Officer | 619.84k | -- | 1960 |
| Mr. John R. Schroer C.F.A. | Chief Financial Officer | -- | -- | 1965 |
| Ms. Sara Klein | Chief Legal Officer & Corporate Secretary | -- | -- | 1965 |
| Mr. Derrick Richardson | Senior Vice President of People & Culture | -- | -- | 1971 |
| Ms. Claire Langrish Ph.D. | Senior VP & Head of Immunology and Translational Science | -- | -- | -- |
| Mr. Philip Nunn Ph.D. | Senior VP of Pharmacology & Project Team Leader | -- | -- | -- |
| Dr. Jorn Drappa M.D., Ph.D. | Chief Medical Officer | -- | -- | 1965 |
| Mr. Mark Bradley | Chief Development Officer | -- | -- | 1966 |
Alumis Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 168
Description
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Corporate Governance
Upcoming Events
March 19, 2025 at 8:05 PM UTC
Alumis Inc. Earnings Date
Recent Events
April 2, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
March 11, 2025 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions